GUMDROP : UMD - A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy

Created by Nancy Dawson, last modified on Jun 25, 2013
Description:This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy
Link:http://clinicaltrials.gov/ct2/show/NCT01193257
Site:University Of Maryland
Principal Investigator:Heather Mannuel, MD